Indication
As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high‐grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first line platinum‐based chemotherapy.

Medicine details

Medicine name:
olaparib (Lynparza)
SMC ID:
SMC2209
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q4 2019
SMC meeting date:
Q4 2019
Patient group submission deadline:
02 September 2019